Literature DB >> 26550261

Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression.

Ai-Hong Jin1, Zhao-Lian Wei1.   

Abstract

OBJECTIVE: The aim of this study is to investigate the sensitivity change and the preliminary mechanism of ovarian cancer cells on the resistant to chemotherapeutic drugs by inhibiting miR-23a expression.
METHODS: The ovarian cancer cell lines A2780 was administrated with antagomir-23a and platinum, and then the cell proliferation inhibition rate was determined by MTT assay. The cell cycle distribution was detected by flow cytometric analysis. The apoptotic morphological changes were analyzed by Hoechst33258 staining. The glycoprotein P-gp expression changes were detected by Western blot analysis.
RESULTS: The cell proliferation inhibition rate increased significantly after the administration of miR-23a and platinum (P<0.01). The middle concentration of drug efficacy IC50 in experimental group decreased by 83.76% compared with that in control group, which was 17.89 μmol/L vs 110.18 μmol/L (P<0.01). The cell lines A2780 were arrested in G0/G1 phase and apoptosis rate kept increasing (P<0.05). The cell nuclei stained by Hoechst33258 were obviously enhanced and demonstrated apoptosis morphology, such as condense, pyknosis. Compared with control group, the levels of P-gp protein expression in experimental group decreased along with the increase of the cisplatin concentration (P<0.05).
CONCLUSION: The inhibition of miR-23a expression could significantly increase the sensitivity of cisplatin towards tumor cells, and it was probably because the negative regulatory factors of miR-23a target genes was released, and as a result, the expression of P-gp protein was inhibited.

Entities:  

Keywords:  MicroRNA; cisplatin; drug resistance; ovarian cancer

Year:  2015        PMID: 26550261      PMCID: PMC4612946     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  11 in total

1.  Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling.

Authors:  Shin-Ichi Nishina; Hidenori Shiraha; Yutaka Nakanishi; Shigetomi Tanaka; Minoru Matsubara; Nobuyuki Takaoka; Masayuki Uemura; Shigeru Horiguchi; Junro Kataoka; Masaya Iwamuro; Takahito Yagi; Kazuhide Yamamoto
Journal:  Oncol Rep       Date:  2011-05-31       Impact factor: 3.906

Review 2.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

3.  A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Authors:  Robert M Wenham; James Lapolla; Hui-Yi Lin; Sachin M Apte; Johnathan M Lancaster; Patricia L Judson; Jesus Gonzalez-Bosquet; Amber Herschberger; Laura J Havrilesky; Angeles Alvarez Secord
Journal:  Gynecol Oncol       Date:  2013-04-25       Impact factor: 5.482

4.  Overexpression of Lewis(y) antigen protects ovarian cancer RMG-1 cells from carboplatin-induced apoptosis by the upregulation of Topo-I and Topo-II β.

Authors:  Changzhi Wang; Limei Yan; Yifei Wang; Bei Lin; Shuice Liu; Quanrong Li; Lili Gao; Shulan Zhang; Masao Iwamori
Journal:  Anat Rec (Hoboken)       Date:  2011-05-03       Impact factor: 2.064

5.  Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.

Authors:  Paweł Surowiak; Verena Materna; Adam Maciejczyk; Marek Pudełko; Ewa Markwitz; Marek Spaczyński; Manfred Dietel; Maciej Zabel; Hermann Lage
Journal:  Virchows Arch       Date:  2007-01-19       Impact factor: 4.064

Review 6.  Factors affecting response of chemotherapy in women with ovarian cancer.

Authors:  J Lubin; A Markowska; P Knapp
Journal:  Eur J Gynaecol Oncol       Date:  2012       Impact factor: 0.196

Review 7.  Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases.

Authors:  Ravindresh Chhabra; Richa Dubey; Neeru Saini
Journal:  Mol Cancer       Date:  2010-09-03       Impact factor: 27.401

8.  Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.

Authors:  Yun Zheng; Rui Wang; Hai-Zhu Song; Ban-Zhou Pan; You-Wei Zhang; Long-Bang Chen
Journal:  Int J Biochem Cell Biol       Date:  2013-07-24       Impact factor: 5.085

9.  MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.

Authors:  Mengru Cao; Masahiro Seike; Chie Soeno; Hideaki Mizutani; Kazuhiro Kitamura; Yuji Minegishi; Rintaro Noro; Akinobu Yoshimura; Li Cai; Akihiko Gemma
Journal:  Int J Oncol       Date:  2012-06-28       Impact factor: 5.650

Review 10.  Role of microRNAs in lung development and pulmonary diseases.

Authors:  Roberto Sessa; Akiko Hata
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

View more
  7 in total

1.  Overexpression of suppressor of IKBKE 1 is associated with vincristine resistance in colon cancer cells.

Authors:  Chun-Peng Zhao; Zhong-Jie Xu; Qing Guo; Yun-Xiao Li; Xiang-Zheng Gao; Yi-You Peng
Journal:  Biomed Rep       Date:  2016-09-21

2.  MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.

Authors:  Ru-Jin Zhuang; Xiao-Xu Bai; Wei Liu
Journal:  Cancer Biol Ther       Date:  2019-03-12       Impact factor: 4.742

3.  Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer.

Authors:  Xiaoli Xu; Zhiguo Zheng; Lanlan Jia; Shasha Suo; Bowen Liu; Tianning Shao; Qinqing Tu; Yuejin Hua; Hong Xu
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

4.  The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53.

Authors:  Ying Ye; Guangdong Wang; Guoyu Wang; Juhua Zhuang; Saifei He; Yanan Song; Jing Ni; Wei Xia; Jiening Wang
Journal:  Front Physiol       Date:  2017-11-10       Impact factor: 4.566

Review 5.  Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Cancer Drug Resist       Date:  2019-06-19

6.  Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Authors:  Stefan Hatzl; Olivia Geiger; Maja Kim Kuepper; Veronica Caraffini; Till Seime; Tobias Furlan; Erika Nussbaumer; Rotraud Wieser; Martin Pichler; Marcel Scheideler; Katarzyna Nowek; Mojca Jongen-Lavrencic; Franz Quehenberger; Albert Wölfler; Jakob Troppmair; Heinz Sill; Armin Zebisch
Journal:  Cancer Res       Date:  2016-04-15       Impact factor: 12.701

7.  Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Hiroki Takeshita; Mahito Miyamae; Takuma Ohashi; Wataru Okajima; Taisuke Imamura; Jun Kiuchi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Oncotarget       Date:  2016-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.